Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CD68 CRISPR/Cas9 KO Plasmid (m): sc-419565
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CD68 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CD68 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CD68 Antibody (KP1): sc-20060
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD68 CRISPR/Cas9 KO Plasmid (m) | sc-419565 | 20 µg | $397.00 |
Overview
Cd68 encodes CD68, a heavily glycosylated lysosomal/endosomal membrane protein enriched in monocytes, tissue macrophages, microglia, dendritic cells, and osteoclasts. It is commonly used as a marker of phagocyte lineage and is associated with endocytosis, phagolysosomal maturation, antigen processing, and innate immune activation programs that shape inflammatory signaling. CD68-positive myeloid populations influence tissue remodeling, lipid handling, and cytokine networks within the tumor microenvironment and in chronic inflammatory contexts. Altered Cd68 expression and CD68+ cell accumulation are frequently studied in neuroinflammation, atherosclerosis, fibrosis, and autoimmune disease models as readouts of macrophage/microglial activation and infiltration.
CD68 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Cd68 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Cd68 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Cd68 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CD68 protein expression.
This CRISPR knockout system enables efficient generation of Cd68-deficient cell models for investigation of CD68 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Cd68 exon(s) critical for CD68 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Cd68 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CD68 CRISPR/Cas9 KO Plasmid (m) and CD68 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Cd68 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CD68 HDR Plasmid (m) and CD68 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Cd68 homology arms to support homology-directed repair at defined Cd68 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.